modelR03DA55
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | AminophyllineCombinations | |
| ATC code: | R03DA55 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 2.8 | mL/min/kg |
| other parameters in model implementation | ||
Aminophylline is a bronchodilator that contains theophylline and ethylenediamine, used to relieve symptoms of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. It acts by relaxing smooth muscles in the airways and is generally administered in acute exacerbations of asthma or bronchospasm. The combinations formulation is still approved and in clinical use today, particularly in emergency settings.
Pharmacokinetics
Estimated pharmacokinetic parameters for adult individuals following intravenous administration based on available theophylline/aminophylline PK data; no published PK model specific for aminophylline, combinations (ATC R03DA55) found.
References
Maxwell-Rubin, M, et al., & Godley, PJ (1994). Adequacy of recommended aminophylline loading doses in children. American journal of hospital pharmacy 51(13) 1667–1671. PUBMED:https://pubmed.ncbi.nlm.nih.gov/7942891
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)